Insmed, Inc. (NASDAQ:INSM) Stock Has Consensus Price Target of $200.30

Insmed, Inc. (NASDAQ:INSM) has received a consensus recommendation of “Moderate Buy” from the twenty-five research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, twenty-two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $198.91.

Several analysts recently issued reports on the company. Jefferies Financial Group reiterated a “buy” rating and set a $175.00 target price on shares of Insmed in a report on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research note on Thursday, October 15th. Morgan Stanley decreased their target price on Insmed from $218.00 to $213.00 and set an “overweight” rating for the company in a research report on Wednesday. Roth Capital reaffirmed a “buy” rating and issued a $198.00 price objective (down from $212.00) on shares of Insmed in a report on Tuesday, September 15th. Finally, JPMorgan Chase & Co. cut their price target on Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a report on Monday, August 10th.

Insmed Stock Up 1.1%

NASDAQ INSM opened at $95.06 on Tuesday. The stock’s 50 day moving average is $115.86 and its two-hundred day moving average is $116.10. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74. Insmed has a 1-year low of $90.39 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.61. The firm had revenue of $425.49 million for the quarter, compared to analyst estimates of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The company’s revenue was up 296.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.70) EPS. As a group, equities analysts expect that Insmed will post -1.59 EPS for the current year.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Analyst upgrade: Roth MKM initiated or reiterated a Buy rating on Insmed, providing positive third-party support for the investment case and potentially improving investor sentiment. Insmed Gets a Buy from Roth MKM
• Positive Sentiment: Board strengthened: Insmed appointed former Sanofi and Novartis CEO Paul Hudson and biopharma executive Kiran Koppikar to its board. The additions could enhance commercialization, global operations and strategic expertise as the company expands its product portfolio. Insmed Names Hudson and Koppikar to Board
• Positive Sentiment: Clinical durability: Extension-study results for TPIP reportedly showed promise in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Positive longer-term data support the potential value of Insmed’s pipeline and future growth opportunities. Extension Studies in TPIP Show Promise
• Positive Sentiment: Japan expansion: Insmed introduced Brinsupri 25 mg tablets in Japan for non-cystic fibrosis bronchiectasis, marking additional international commercialization and a potential source of revenue growth. Insmed Introduces Brinsupri in Japan
• Neutral Sentiment: Industry coverage highlighted Insmed among notable biopharma developments, but the available headline does not identify a separate material announcement or financial catalyst. The Escalator: CSL, Insmed, Amgen and More
• Negative Sentiment: Earnings risk: Zacks said Insmed may report a negative earnings surprise in next week’s release because it lacks the favorable combination of earnings-estimate revisions and other indicators typically associated with a beat. That could limit near-term upside and increase volatility around results. Insmed May Report Negative Earnings

Insider Buying and Selling at Insmed

In related news, COO Roger Adsett sold 239,850 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $133.27, for a total value of $31,964,809.50. Following the transaction, the chief operating officer owned 98,744 shares of the company’s stock, valued at $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David Brennan sold 25,000 shares of the company’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the sale, the director directly owned 39,238 shares of the company’s stock, valued at $4,865,512. This trade represents a 38.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is currently owned by insiders.

Institutional Trading of Insmed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INSM. Reflection Asset Management bought a new stake in shares of Insmed during the 4th quarter valued at about $30,000. Virginia Estate & Retirement Planning Advisors Inc. purchased a new stake in Insmed in the third quarter worth $29,000. SBI Securities Co. Ltd. boosted its holdings in shares of Insmed by 69.4% during the 3rd quarter. SBI Securities Co. Ltd. now owns 349 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 143 shares in the last quarter. CX Institutional bought a new stake in shares of Insmed during the 3rd quarter valued at $46,000. Finally, Whittier Trust Co. of Nevada Inc. lifted its position in Insmed by 86.6% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 444 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 206 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.